SCHEMBL7189265

SCHEMBL7189265

CCOC(=O)C(C(=O)c1c(OC)cc(OC)cc1OC)c1ccccc1.O=[PH3]

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 1/20 0.49
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
CYP3A4 P08684 2/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
ATM Q13315 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TACR1 P25103 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
PTPN1 P18031 1/20 0.39
NPC1 O15118 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27554209 0.96 MMP8 (0.50) MMP8TDP1L3MBTL1KMT2AMEN1
SCHEMBL7183694 0.91 KMT2A (0.45) TDP1L3MBTL1KMT2AMEN1CYP3A4
SCHEMBL7186621 0.90 TDP1 (0.42) MMP8TDP1L3MBTL1KMT2AMEN1
SCHEMBL7177656 0.88 MMP8 (0.52) MMP8KMT2AMEN1MAPTCA12
SCHEMBL7189965 0.88 TDP1 (0.43) TDP1L3MBTL1
SCHEMBL7187090 0.88 CA1 (0.44) TDP1L3MBTL1KMT2ACYP3A4TP53
SCHEMBL7175984 0.88 ALDH1A1 (0.40) TDP1L3MBTL1KMT2AMEN1CYP3A4
SCHEMBL7181290 0.87 NPC1 (0.42) CYP3A4TP53NPC1ALDH1A1
SCHEMBL27554103 0.87 KMT2A (0.46) TDP1L3MBTL1KMT2AMEN1CYP3A4
SCHEMBL27500957 0.86 TDP1 (0.43) MMP8TDP1L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MMP8 4404/4885TDP1 4234/4885L3MBTL1 302/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MMP8 4586/4885TDP1 4275/4885L3MBTL1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.